Data as of 15/02/2019

Risk level



Recommended investment horizon : > 10 years

Average annual performance since launch

12,89 %

Performance as at 15/02/2019

2016 9,51 %
2017 20,59 %
2018 0,87 %
Since 01/01/2019 11,89 %
Over the last 12 months 10,21 %
Over 3 years 61,11 %
Since launch 48,34 %
Asset breakdown
Equities 98,26 %
Cash 1,74 %
Breakdown by currency
USD 97,42 %
CAD 2,47 %
EUR 0,12 %
Main positions
Resmed Inc 3,42 %
Check Point Software Technologies Ltd 3,07 %
Cognex Corp 3,02 %
Ulta Beauty Inc 3,00 %
Tractor Supply Co 2,87 %

Investment objective and policy

BL-American Smaller Companies invests up to 80% of its assets in shares of American companies with a market capitalization below 20 billion USD. Selected companies have a well-defined business model with a clear market strategy. The fund invests in companies with a strong competitive advantage, showing a sustainable superior return profile and generating high and consistent levels of free-cash flow. In combination with a solid financial situation. Investment decisions are based on strict valuation and quality criteria.

Management report - 4th Quarter 2018

The final quarter of 2018 was not good for equity markets. Investors have had to contend with rising US central bank interest rates, a sharp slowdown in eurozone business confidence, weaker Chinese growth and rising geopolitical concerns (including Brexit, Italian politics and the ongoing trade conflict between the US and China). This all proved an indigestible cocktail for investors. In this environment the BL-American Smaller Companies Fund (retail share class capitalization net of fees in USD) outperformed its Benchmark, the MSCI US Small + Mid Cap NR USD Index, by 5,30%. In absolute terms, the fund showed a negative performance of 12,15%. During the quarter, we initiated a position in Masimo. The company is a medical device business focusing on noninvasive patient monitoring. It began by developing superior signal processing algorithms to measure blood oxygenation levels through pulse oximetry and has expanded this expertise into a wide range of measurements and applications. The recent settlement and joint venture agreement with Philips represents one of the most significant milestones in the company's history. The company has built a strong moat for itself in patient monitoring through strong intangible assets protected by patents and switching costs that have been embedded in its installed base. A strong top-down push to integrate Masimo sensor technology in Philips' leading line of patient monitors will expand Masimo's share of the installed base while upgrading customers to the company's next-generation rainbow SET. This should help to not only better protect its intangibles-based moat source, but also raise the bar for competitors looking to catch up. On the other hand, we sold Stericycle and Hain Celestial. Stericycle trimmed once more their 2018 guidance, which implies a weaker Q4 2018. We expect 2019 to be another transition year with EPS likely declining further. In our view, the company continues to face numerous challenges and visibility into forecasts remains low. Hain's lackluster near-term sales/operating outlook and uncertainty around the scope and timing of its turnaround plan, combined with the likelihood of a significant cut to FY2019 guidance from the recently hired CEO, convinced us to sell the position during the month. The company's portfolio of healthier brands, turned out to be less competitive then we though at the time we took a position. The top 5 contributors in the quarter were Church & Dwight, Lancaster Colony, Lamb Weston, McCormick and Clorox. The top 5 detractors were Align Technology, Welbilt, Cognex, Laboratory Corp and Sensient Technologies.

General information

Net Asset Value 
Calculated Every business day
NAV class B capitalisation shares (15/02/2019) 148,80 USD
CODES Internal capitalisation code : 29339088
ISIN capitalisation code : LU1305478775
WKN capitalisation code : A1421A
Net assets (million) 234,89 USD
Launch date 13/11/2015

Before making any decision to subscribe, customers must ensure they have understood the product, having measured the risks associated with it and consulted their own advisers on the appropriateness of the product for their particular financial situation, taking into account legal, tax and accounting aspects. This fact sheet has been drawn up for information purposes and shall in no event be considered a solicitation to buy or an offer to sell securities or other financial instruments. Information provided to the interested party does not constitute legal or fiscal advice and the Bank shall not be held liable for such information. The securities referred to in this document may cause the investor to incur significant risk and may not be appropriate for all investors. Such risks include market risks, high volatility, credit risk, liquidity risk and interest-rate risk. There is no guarantee that the securities described in this document will achieve their investment objectives. Past performance is no indication of future returns. The Bank shall not be held liable for the future performance of these securities. Potential investors must ensure that they understand the risks of investing in such products and should only take an investment decision after giving careful consideration, together with their professional advisers, to the appropriateness of this investment to their specific financial situation, particularly with regard to legal, tax and accounting aspects. We have made every effort to verify that the information presented in this document is correct, in particular the estimated values, opinions and other estimates. Nevertheless, no guarantee can be given as to the validity, timeliness, completeness, correctness or accuracy of the information, which is provided for guidance only. Information may be subject to change without prior notice.